New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Advancements in paediatric Acute lymphoblastic leukemia management

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

Choosing the right patients for transplant

Choosing Wisely for young women with breast cancer: Medical therapy

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy

ESMO 2024: Latest in EGFR mutated NSCLC

Improved structure preservation with neo-adjuvant platinum-based chemo in patients with resectable NPNSCC

Breastfeeding after breast cancer is safe

Repeat immune checkpoint inhibitor therapy not recommended for aRCC